A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Epoetin Alfa-Epbx (RETACRIT)

First FDA approval2018-06-18
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$42.5M in CY2024 Part D spend75K claims · 24K beneficiaries · 329 plans surveyed

Lowest NADAC
$21.98/unit
3 NDCs benchmarked, lowest of all strengths.
Average NADAC
$117.12
Across all dosage forms in distribution.
Highest NADAC
$219.39
Wide spread — brand-strength NDCs still in market.
Plans with PA
1744 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Epoetin Alfa-Epbx used for?

Epoetin Alfa-Epbx is a this drug class medication tracked in Medicare Part D.

Is there a generic for Epoetin Alfa-Epbx?

No. Epoetin Alfa-Epbx is brand-only with no generic equivalents currently in market.

How much does my plan pay for Epoetin Alfa-Epbx?

Across 329 Part D plans, Epoetin Alfa-Epbx averages $117.12/unit (NADAC). Lowest available: $21.98/unit. Highest in distribution: $219.39/unit.

Is Epoetin Alfa-Epbx on the FDA shortage list?

No. Epoetin Alfa-Epbx is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Drug class1 alternative in D1
01
Epoetin Alfa
Brand: EPOGEN
$32.36Lowest NADAC
0Generic mfrs
$244.7MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (3 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.